Cell Biotech (CEO Myung-Jun Jeong), which operates the strong probiotic brand 'DUOLAC', continued its growth with both sales and operating profit increasing in 2025.
Cell Biotech announced on the 23rd that its preliminary 2025 performance forecasts recorded sales of KRW 53.3 billion and operating profit of KRW 7.9 billion. This represents a 6.8% increase in sales and a 16.4% increase in operating profit compared to 2024, with net income reaching KRW 9.6 billion.
The improved performance is attributed to brisk overseas exports. Driven by growing global demand for K-lactic acid bacteria, the company achieved stable export growth, particularly in European and Asian markets. Exports to Denmark, particularly through the Duolac brand, drove sales growth.
Based on its proprietary CBT lactic acid bacteria development capabilities and global standard production technology, Cell Biotech exports its products to 55 countries worldwide. It has ranked first in domestic probiotic exports for 12 consecutive years and has strengthened its global presence by establishing an overseas branch in Denmark, achieving second-largest local market share.
The advertising campaign, "221 times stronger than probiotics, Duolac," also had a positive impact in the domestic market. Emphasizing Dual Coating technology and conveying a message focused on intestinal survival rates, the campaign resulted in increased new customer acquisition and repeat purchases on the official website.
A Cell Biotech official said, “As global trust and demand for K-lactic acid bacteria continue to grow, we have been able to maintain a stable growth trend in both exports and domestic sales,” and added, “We will continue to strengthen product competitiveness and expand overseas markets based on our differentiated technological prowess and global network.”
- See more related articles
You must be logged in to post a comment.